Paper Details

  1. Home
  2. Paper Details

Treatment of multiple myeloma according to the extension of the disease: a prospective, randomised study comparing a less with a more aggressive cystostatic policy. Cooperative Group of Study and Treatment of Multiple Myeloma.

Author: AlberioF, BarbaranoL, BrugnatelliS, De PaoliA, Di StasiM, LuoniR, MoraO, RiccardiA, SpaneddaR, UcciG

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study investigated the impact of treatment intensity on the outcome of multiple myeloma (MM). Patients were divided into stages based on disease severity and received different induction therapies (melphalan and prednisone (MPH-P) or combination chemotherapy). Response rates and survival times were similar regardless of the intensity of induction therapy or whether maintenance therapy was continued. While combination chemotherapy was more effective in inducing a first response, it also caused more side effects. The study concluded that MPH-P is a safe and effective first-line treatment for MM, and that delaying treatment in early stages may be possible.
Paper Details　
Original Abstract of the Article :
The purpose of the study was to ascertain whether the prognostic significance of staging in multiple myeloma (MM) is influenced by the aggressiveness of effective induction treatment and/or by continuing or discontinuing maintenance chemotherapy. Patients with untreated stage I MM (defined according...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1038/bjc.1994.474

データ提供：米国国立医学図書館（NLM）

Multiple Myeloma: Tailoring Treatment to the Individual

Multiple myeloma is a complex and challenging cancer that requires individualized treatment strategies. This research explores the impact of treatment intensity on patient outcomes in multiple myeloma. The authors conducted a prospective, randomized study comparing a less aggressive treatment approach with a more aggressive approach, analyzing the effectiveness and side effects of each strategy.

Treatment Intensity: A Balancing Act in Multiple Myeloma

The study found that both less aggressive and more aggressive treatment approaches achieved similar disease control in patients with multiple myeloma. While the more aggressive approach resulted in a greater number of side effects, it did not significantly improve overall survival. This finding highlights the importance of considering individual patient characteristics, such as age, health status, and disease stage, when determining the most appropriate treatment strategy.

Navigating the Complex Terrain of Cancer Treatment

This study underscores the need for a personalized approach to cancer treatment, carefully weighing the benefits and risks of different treatment options. The researchers emphasize that a one-size-fits-all approach is not always optimal, and that individual patient needs should guide treatment decisions. Ongoing research and monitoring are essential to refine treatment strategies and improve patient outcomes.

Dr.Camel's Conclusion

Treating multiple myeloma is like traversing a vast and unforgiving desert. This research, like a guide through the shifting sands, provides valuable insights into the impact of treatment intensity on patient outcomes. It reminds us that a personalized approach, tailored to individual patient needs, is essential for navigating the complex terrain of cancer treatment, maximizing benefits while minimizing risks.

Date :
  1. Date Completed 1995-01-03
  2. Date Revised 2022-04-09
Further Info :

Pubmed ID

7981078

DOI: Digital Object Identifier

10.1038/bjc.1994.474

Related Literature

Article Analysis
・Effective treatment of multiple myeloma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.